We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the use of levodopa-based drugs for managing Parkinson’s disease.
The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented at the 7th Congress of the European Academy of Neurology – Virtual 2021.
Question:
- Levodopa-based drugs are currently the most effective tools for managing Parkinson’s disease – what limitations do these drugs have in practice?
Disclosures: Heinz Reichmann was acting on Advisory Boards and gave lectures and received research grants within the last 5 years from Bial, Desitin, Eisai, Kyowa-Kirin, Merz, Novartis, UCB Pharma and Zambon.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of the EAN Congress, Virtual 2021
